Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006014 · ClinicalTrials.gov registry record · Phase 2
SU5416 in Treating Patients With Malignant Mesothelioma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00006014: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00006014 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006014, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of SU5416 in treating patients who have malignant mesothelioma. SU5416 may stop the growth of malignant mesothelioma by stopping blood flow to the tumor.
Interventions
- DRUG semaxanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2000-08 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006014
The ClinicalTrials.gov registry entry for NCT00006014 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which semaxanib is the first listed.
NCT00006014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006014 about?
NCT00006014 is a clinical study titled "SU5416 in Treating Patients With Malignant Mesothelioma". Phase II trial to study the effectiveness of SU5416 in treating patients who have malignant mesothelioma. SU5416 may stop the growth of malignant mesothelioma by stopping blood flow to the tumor.
What is the current status of trial NCT00006014?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2000-08. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00006014?
The interventions under investigation include: semaxanib (DRUG).
Who is sponsoring clinical trial NCT00006014?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.